VEGF News and Research

RSS

VEGF is a substance made by cells that stimulates new blood vessel formation. Also called vascular endothelial growth factor.

Saving sight of millions by making eye injections safe and comfortable

Two eye surgeons have written a first-of-its-kind book to save the sight of millions of patients around the world by making eye injections safe and comfortable.

7 Aug 2018

Scientists move one step further in developing eye drops to treat age-related macular degeneration

Scientists at the University of Birmingham are one step closer to developing an eye drop that could revolutionize treatment for age-related macular degeneration.

20 Jul 2018

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix™, Inc., a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, has announced the resubmission of the Company's New Drug Application to the U.S. Food and Drug Administration for its lead product candidate DEXTENZA™ 0.4mg, for the treatment of ocular pain following ophthalmic surgery.

30 Jun 2018

Researchers explore targeted second-line treatment for colorectal cancer

Targeted therapy with anti-VEGF and anti-EGFR antibodies both improve outcomes when added to chemotherapy in the treatment of colorectal cancer. However, some previous studies suggested the combination of the two antibodies may have a negative interaction.

5 Jun 2018

Researchers develop injectable bandage to stop fatal blood loss, activate wound healing

While several products are available to quickly seal surface wounds, rapidly stopping fatal internal bleeding has proven more difficult.

22 May 2018

PanOptica doses first patient in Phase 1/2 dose-ranging clinical trial of PAN-90806

PanOptica, Inc., a private biopharmaceutical company focused on developing innovative ophthalmology therapies, today announced that the Company has dosed the first patient in a Phase 1/2 dose-ranging clinical trial of PAN-90806, a once-daily topical eye drop formulation of a small-molecule anti-vascular endothelial growth factor (anti-VEGF) for the treatment of neovascular eye diseases.

22 May 2018

Non-aspirin NSAID use linked to shorter survival in patients with metastatic renal cell carcinoma

Ibuprofen, aspirin, and other non-steroidal anti-inflammatory medications are among the most commonly utilized medications in the United States. Primarily for treating pain, inflammation, and preventing cardiovascular disease, NSAIDs' promising anti-cancer properties have been highlighted by a growing body of data in recent years.

2 May 2018

Neonicotinoids may impact human health by disrupting hormonal systems, shows study

Neonicotinoids are currently the most widely used pesticides in the world and frequently make headlines because of their harmful effects on honeybees and other insect pollinators

27 Apr 2018

Ludwig scientists develop and test individualized ovarian cancer vaccine

A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.

11 Apr 2018

Novel biomarker helps optimize anticancer therapy

Researchers have identified a biomarker that can be used to visualize blood vessel activity and optimize the timing of anticancer therapy.

9 Apr 2018

Vascular stabilization biomarker helps optimize timing of anticancer therapies

Angiogenesis, the formation of new blood vessels, is essential for tumor growth. A new study reported in The American Journal of Pathology describes a vascular stabilization biomarker that can visualize blood vessel activity, thus optimizing the timing of anticancer therapies including anti-angiogenics.

9 Apr 2018

Research reveals neuroprotective mechanisms of gene and cell medications for spinal cord injuries

A joint paper with Kazan State Medical University appeared in Stem Cells International. The research was based at the Gene and Cell Technologies Lab of Kazan University.

8 Mar 2018

New marker involved in lymphatic system linked to increased risk of heart failure

Researchers at Lund University in Sweden have found a new marker in the blood that is associated with an increased risk of heart failure.

7 Mar 2018

Geneva researchers highlight new way to control tumor progression

For a tumor to grow, it must develop blood vessels that supply nutrients and oxygen. Preventing tumor vascularization is therefore an interesting anti-tumor therapy that has been explored over the last ten years.

2 Feb 2018

New organ-on-a-chip technology provides simple setting to study blood vessel formation

Researchers at the Institute of Industrial Science, the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel formation and drugs targeting this event.

31 Jan 2018

Scientists discover new target for anti-angiogenic tumor therapy

Actively growing tumors have a high demand for oxygen and nutrients. Therefore, they stimulate the growth of blood vessels.

23 Jan 2018

Researchers block common siren call of glioblastoma and metastatic breast cancer

Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

23 Jan 2018

Administration of two proteins shown to counteract neurodegeneration in Parkinson's disease

A combination therapy made up of two neurotrophic factors can reduce the degenerative effects of Parkinson’s disease, shows new research.

15 Jan 2018

Synergy between two neurotrophic factors exerts beneficial effect in early phase of Parkinson’s disease

Parkinson's disease is currently the second most widespread neurogenerative pathology. Current therapies are mainly of a replacement type and pose problems in the long term, so the challenge is to establish an early diagnosis and develop neuroprotective and neurorestorative therapies that will allow the symptoms of the disease to be slowed down or even reversed.

12 Jan 2018

Study suggests potential means of stalling or even reversing diabetes-related blindness

Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels in the retina, leading to blindness.

3 Jan 2018